ArticleBreast cancer research and treatment2026
Early first-line systemic anticancer therapeutic attrition after metastatic recurrence in triple-negative breast cancer following neoadjuvant chemo-immunotherapy: a multicenter real-world study.
Palma Fedele et al.PubMed ↗Publisher ↗
No numbers read from the abstract.